BridgeBio Pharma Inc.
BridgeBio Announces Strong Demand for Attruby and Progress on Clinical Trials
Summary
BridgeBio Pharma, Inc. reported significant commercial progress and pipeline updates in a press release on January 13, 2025. The company announced strong initial demand for Attruby (acoramidis) with 430 scripts written by 248 unique healthcare providers since FDA approval, indicating broad uptake across academic and community centers. Additionally, BridgeBio disclosed that it has fully enrolled three major Phase 3 clinical trials for BBP-418 (LGMD2I/R9), encaleret (ADH1), and infigratinib (achondroplasia), with readouts expected in the second half of 2025. Financially, the company is well-positioned with $406M in cash and expects to receive an additional $500M from the royalty facility upon FDA approval and $105M from regulatory milestones in Europe and Japan in the first half of 2025.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement